Each month, we highlight one of our amazing members doing amazing things in digital health and beyond. Our July member feature is written by and about on one of our newest members, Curenetics.
Curenetics was founded by Sola Adeleke, a cancer specialist with over 10 years experience in the field. He is a clinical oncology registrar in the southeast London training pathway. Curenetics is aiming to work towards personalising cancer treatment using AI algorithms.
What are Curenetics doing?
Cancer treatment over the years has got more clever, sophisticated and effective. Most of the advances in cancer therapies have been due to our ability to better understand the cancer genome and in finding ways to target cancer cells and destroy them. However, it comes at a price; cancer treatments have become more and more expensive and even unaffordable to many. Beyond just the cost of treatments, cancers often find a way to beat the treatment and eventually relapse. This shows cancer genomics-based treatment alone might not be the answer. At Curenetics, we have developed an AI-based platform that can better analyse the cancer genomic profile in greater detail than what has been developed before. This will be combined with patient imaging data (their scans) and their unique clinical histories to identify the best treatment options which will be most suitable for a patient. In summary, cancer treatment is not one size fits all and curenetics aim to personalise cancer treatment for each patient’s unique body.
In the last year, we have secured multiple grant funding which has allowed us to hire a team of data scientists and cancer biologists to work on various AI-driven cancer diagnostic/predictive tools. For instance, we have now developed a simple, AI-driven blood-based test for diagnosing 11 common cancers. This has been shown to have an accuracy of >90% and will now move into clinical trial testing. One of our other projects is the use of our AI platform in the prediction of Graft versus host disease in patients undergoing hematopoietic stem cell transplants. We are developing these products with some of the top London hospitals and academic partners.
What is next for Curenetics?
Curenetics is aiming to raise seed funding (over the next 3 months) to expand our R&D and validation work. We also plan to forge partnerships with hospitals and academic institutions nationally and internationally to expand our customer base. We will be filing our first patent application at the end of the summer.
Words: Curenetics
We’re excited to have Curenetics join the Health Foundry community. If you’d like to connect with Sola and the rest of the team, contact them here.